PANDAS Physicians Network Awards Funding to the Agalliu Lab for Immune Mediated OCD, PANDAS/PANS Research
MOORESVILLE, NC, UNITED STATES, April 3, 2025 / EINPresswire.com / -- The PANDAS Physicians Network is pleased to award funding to the Agalliu Lab in the Department of Neurology at Columbia University Irving Medical Center. This award will enhance our understanding of how the adaptive and innate immune systems contribute to post-infectious sequelae in the brain. Through whole exome sequencing of children with PANDAS, researchers in the lab of Dr. Dritan Agalliu identified RXRA as a potential genetic risk factor for the disease. This award will support an ongoing study conducted by Dr. Uğur Akcan which will provide insight into the mechanisms by which the RXRA genetic risk factor identified in children with PANDAS affects the immune responses that triggers immune-mediated neuropsychological changes, including obsessive-compulsive behaviors.
According to Dr. Akcan, 'Our research will provide important insights into how the immune system and inflammation affect brain function, particularly in children with PANDAS/PANS. It underscores the importance of studying the neuroimmune axis, which connects the immune system and the brain, as a vital area of biomedical research. The findings challenge the traditional focus on neurons alone in psychiatric disorders. Instead, they emphasize the role of other central nervous system (CNS) cells, particularly those governing immune functions, in the development of neuropsychiatric symptoms after infections. Moreover, the study highlights that microglia, the brain's immune protectors, are crucial players in the development of behavioral abnormalities seen in post-infectious obsessive-compulsive disorders. This research also points to genetic risk factors like RXRA mutations as potential contributors to psychiatric disorders, including obsessive-compulsive disorders.'
We celebrate the continued excellence from the Agalliu Lab and congratulate Dr. Agalliu and Dr. Akcan on their accomplishments. CLICK HERE to learn more about this work and contribute to the Agalliu Lab.
PANDAS Physicians Network (PPN) is a non-profit organization that provides PANS/PANDAS resources to clinicians while supporting research. Our vision is that PANS/PANDAS will become easily diagnosed and treated with accessible therapies that dramatically reduce suffering and lead to a cure. Learn more at www.pandasppn.org.
X
YouTube
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 days ago
- Medscape
PANS and PANDAS: Diagnosis and Treatment
While anxiety symptoms are common in prepubertal children, they occasionally present suddenly and with a high degree of severity. In these circumstances, parents may turn to you, the pediatrician, to address the possibility that these syndromes are autoimmune, under the diagnostic umbrellas of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). While the clinical community continues to debate many aspects of these diagnoses, families may seek treatment based on their own online research. Your understanding of what is known about the prevalence and assessment of immune-related neuropsychiatric disorders will help you to provide these patients and their families with meaningful support and responsible guidance for the management of these syndromes. Prevalence and Controversy Susan D. Swick, MD In 1989, researchers studying Sydenham chorea noted a high prevalence of obsessive thoughts and compulsive behaviors in children with rheumatic fever without chorea. Susan Swedo, MD, and colleagues at the National Institutes of Health eventually characterized this syndrome as PANDAS, occurring in 50 children who developed acute-onset obsessive compulsive disorder (OCD), anxiety, or tics with a preceding or concurrent group A streptococcal (GAS) infection. In 2012, PANS or childhood acute-onset neuropsychiatric syndrome was proposed to broaden the criteria to include similar abrupt-onset psychiatric symptoms (OCD and restricted eating) with inciting events other than GAS infection, including mycoplasma, influenza, Lyme disease, or even psychosocial stressors. Reliable prevalence estimates remain elusive, largely because of small numbers, diagnostic uncertainty, and lack of consensus criteria to be applied across studies. In the original studies, the mean age of onset was 6.3 years for tics and 7.4 years for OCD symptoms. The ratio of males to females was 4.7 to 1 under the age of 8 years. In one prospective study, only 10 cases were identified among 30,000 participants with throat cultures that were positive for GAS. The broader category of PANS has proven even more difficult to quantify, given its heterogeneous triggers. The high rate of GAS exposure and anxiety disorders in prepubertal children make the establishment of a causal link very difficult. Michael S. Jellinek, MD This has led to significant controversy over the diagnosis and treatment of PANDAS and PANS. While there is research interest in the role of the immune system in some psychiatric illnesses, neither diagnosis is listed in the DSM-V or the ICD-10. Nonetheless, there are parents who will come to you with questions about PANS and some small number of children each year who will develop it. Helpfully, the American Academy of Pediatrics (AAP) published a clinical report on PANS (encompassing PANDAS) in March 2025 to provide guidance. Our aim is to review the current guidance and help you use your best clinical judgment to treat all children thoughtfully and responsibly. Clinical Presentation and Assessment The hallmark symptom of PANDAS and PANS is the sudden, dramatic onset of symptoms of OCD, severely restricted food intake, or tic disorder, often appearing literally overnight in a prepubertal child. There are typically multiple severe symptoms starting abruptly together, like an 'explosion.' PANS diagnosis requires concurrent abrupt onset of additional severe neuropsychiatric symptoms in at least two of the following areas: anxiety, emotional lability or depression, irritability or aggression, developmental regression, deterioration in school performance, sensory or motor abnormalities, or somatic signs (sleep disturbances, enuresis, or urinary frequency). When any syndrome is sudden and severe, it is normal for parents to be very concerned and distressed. Express understanding and validation as you begin your assessment, which should include: Clinical History: Timing of symptom onset (Was it abrupt and severe? Did it reach a crescendo in 24-48 hours?) Assessment for signs of Sydenham chorea, Tourette, encephalitis, and anorexia nervosa History of developmental or psychiatric disorders Any recent illnesses, particularly GAS pharyngitis (documented via throat culture) Physical and Neurological Exam: To rule out signs of infection, systemic illness, or neurologic disease Motor examination, with attention to choreiform movements Laboratory Workup: Throat culture or rapid strep with symptomatic pharyngitis (although a negative rapid test may be inaccurate) Routine screening for GAS, antistreptolysin O, and anti-DNase B titers are not recommended by the AAP When the neurological examination is suggestive, lumbar puncture or MRI may be warranted to assess CNS inflammation If there is no evidence of GAS infection, PANDAS is unlikely. In general, the onset of OCD (and other anxiety disorders) is usually gradual and persistent, although children may internalize and hide symptoms until they no longer can. Tic disorders usually begin with isolated, intermittent motor or vocal tics, not an 'explosion.' The presence of cognitive decline, psychosis, catatonia, new seizures, or movement disorders other than tics should lead to an expanded and thorough neurological workup, including for autoimmune encephalitis. The AAP specifies that further laboratory testing and imaging have no evidence to support their use in the workup for PANS. Management Strategies If your assessment suggests PANS, how do you begin treatment? Explain to the family that treatment will address any confirmed infection, psychiatric symptoms, and inflammation. While some children may improve with antibiotics alone (symptoms may resolve fully within several weeks), most children will require treatment of persistent psychiatric symptoms even when all signs of GAS infection have resolved. Treatment typically involves three concurrent pathways: 1. Medical Management of Infection and Inflammation: Start with treatment of the GAS infection, if there is one. Antibiotics: The AAP recommends a standard (10-day) course with appropriate antibiotics for a positive culture in a symptomatic child. The AAP does not recommend prophylactic or long-term use of antibiotics, or treatment of asymptomatic positive culture (colonization). Some children's neuropsychiatric symptoms respond to antibiotics; others do not. The AAP recommends a standard (10-day) course with appropriate antibiotics for a positive culture in a symptomatic child. The AAP does not recommend prophylactic or long-term use of antibiotics, or treatment of asymptomatic positive culture (colonization). Some children's neuropsychiatric symptoms respond to antibiotics; others do not. Anti-inflammatory Treatment: The AAP does not recommend NSAIDS or more aggressive anti-inflammatories, given the absence of evidence and considerable side effects. The AAP does not recommend NSAIDS or more aggressive anti-inflammatories, given the absence of evidence and considerable side effects. Immune Modulation: Invasive therapies like intravenous immunoglobulin or plasmapheresis have no evidence to support their use in PANS. Patients with severe, persistent neuropsychiatric symptoms should have an expanded neurological and rheumatologic assessment before any consideration of these treatments. 2. Psychiatric Symptom Management: An infection may have caused the psychiatric symptoms or simply exacerbated or unmasked an underlying illness that will require independent treatment. OCD: Cognitive behavioral therapy (CBT) — specifically, exposure and response prevention (ERP) — is the gold standard for managing OCD symptoms, regardless of etiology. Selective serotonin reuptake inhibitors (SSRIs) are similarly effective and the combination of the two has demonstrated superior efficacy to either treatment alone. Each treatment may take 12 weeks or more to be effective. ERP may be difficult to access. SSRIs should be started at low doses and titrated gradually as they may cause temporary activation if started at too high a dose. They are not contraindicated in OCD, anxiety disorders, or PANS, and parents should be offered education to prevent any concern about these effective treatments. Cognitive behavioral therapy (CBT) — specifically, exposure and response prevention (ERP) — is the gold standard for managing OCD symptoms, regardless of etiology. Selective serotonin reuptake inhibitors (SSRIs) are similarly effective and the combination of the two has demonstrated superior efficacy to either treatment alone. Each treatment may take 12 weeks or more to be effective. ERP may be difficult to access. SSRIs should be started at low doses and titrated gradually as they may cause temporary activation if started at too high a dose. They are not contraindicated in OCD, anxiety disorders, or PANS, and parents should be offered education to prevent any concern about these effective treatments. Tics: Tics are only treated when they interfere with a child's function or lead to significant embarrassment or bullying. A behavioral psychotherapy (comprehensive behavioral intervention for tics, CBIT) has demonstrated efficacy. Medications (alpha-2 agonists) have modest efficacy and can be used in more severe cases. Tics are only treated when they interfere with a child's function or lead to significant embarrassment or bullying. A behavioral psychotherapy (comprehensive behavioral intervention for tics, CBIT) has demonstrated efficacy. Medications (alpha-2 agonists) have modest efficacy and can be used in more severe cases. Food Restriction ( Avoidant/Restrictive Food Intake Disorder, ARFID): Almost all children with ARFID and PANS also have underlying OCD. Treatment starts with a medical assessment of nutritional and hydration status and weight restoration and correction of electrolyte abnormalities, if needed. Then CBT (ERP again) is the effective treatment for the avoidant behaviors around food. This is a specialized treatment that requires a clinician who has training in CBT and experience working with ARFID specifically. Avoidant/Restrictive Food Intake Disorder, Almost all children with ARFID and PANS also have underlying OCD. Treatment starts with a medical assessment of nutritional and hydration status and weight restoration and correction of electrolyte abnormalities, if needed. Then CBT (ERP again) is the effective treatment for the avoidant behaviors around food. This is a specialized treatment that requires a clinician who has training in CBT and experience working with ARFID specifically. Additional Symptoms: Sleep disturbances and separation anxiety both can be addressed with CBT, with an additional component of parental skill building to complement and support the child's work. 3. Family Support: The sudden, severe onset of disruptive behavioral symptoms is bound to be very distressing for your patient and particularly for their parents, whatever the cause. Families of children with severe, sudden psychiatric symptoms experience significant stress and distress. If they suspect it might be caused by a current or recent infection, it is important that their pediatrician is genuinely curious about their observations and concerns. Some families may think they have been treated dismissively when they are told that there is 'no evidence' to support their observations. Remember, they are the experts on their children. When they have experienced your genuine curiosity and respect, it will be easier for them to trust your judgment should you conclude that their child may need treatment beyond antibiotics. Support, reassurance, and education are vital. Build a team with a psychiatrist and psychotherapist and engage the school to provide accommodations during treatment (eg, reduced workload and support for attention deficits or anxiety). The Pediatrician is Critical Pediatricians are the first point of contact when children present with symptoms that suggest PANS. Your responsiveness, targeted workup, and collaborative management are critical. Your ability to provide the family with meaningful support will create a strong foundation of trust that will improve the course of their child's care. Given the complex and uncertain nature of these diagnoses, your partnership with the parents is the critical first step. Acknowledge that inflammation is emerging as an important factor in many medical and psychiatric conditions, but that it may not always guide treatment. It should not be a matter of medical illness or psychiatric illness. Help families to understand that even if a strep infection triggered the psychiatric symptoms, they will both need treatment. Treatment may be slow, but with your guidance and partnership the child will recover. A parent's trust in you is the essential foundation for this process. Conclusion PANS and PANDAS are emerging clinical entities residing at the intersection of psychiatry, pediatrics, and immunology. While more research is needed to understand their pathophysiology and optimal treatment strategies, the reality is that affected children may be presenting to your offices today — suffering and in need of thoughtful, coordinated care. Maintain a curious, compassionate posture, acknowledge uncertainty where it exists, and provide clarity about our ability to offer reasonable and effective treatments guided by evidence and good judgment even when there is uncertainty.
Yahoo
28-06-2025
- Yahoo
New Study Finds That A Blood Test For Diabetes Might Actually Predict Alzheimer's Progression
A new study suggests a simple blood test could tell who is at higher risk for rapid cognitive decline with Alzheimer's. The study found that people with higher insulin resistance were up to four times more likely to have rapid cognitive decline. Here's what to know about the test and how to get one. Historically, it has been quite difficult for doctors to predict how fast patients will experience cognitive decline with Alzheimer's disease, especially since the neurodegenerative disease impacts people differently based on a slew of factors. But new research has discovered that a specific blood test may help doctors get more answers, which could, in theory, help them respond more quickly with appropriate treatment and providing patients with more information. (But of course, experts first need to gather more data and perform further studies on the test.) The test measures insulin resistance, a condition where the body's cells don't respond properly to insulin, a hormone that helps escort blood sugar into cells for energy. The latest study finds a link between insulin resistance and Alzheimer's disease progression, helping doctors and patients glean more information about what may be in store. Here's what the study found, plus what neurologists want you to know. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University. The study, which was presented at the European Academy of Neurology Congress 2025, analyzed health records of 315 people without diabetes who had cognitive deficits. Of those, 200 had confirmed cases of Alzheimer's disease. All of the patients had their insulin resistance checked using something called the Triglyceride-Glucose (TyG) index, a way to check insulin resistance, based on fasting triglyceride (a type of fat in the blood) and blood sugar levels, at the start of the study and three years later. The researchers discovered that patients in the mild cognitive impairment group with higher TyG levels had their cognitive health deteriorate a lot faster than those who were lower on the TyG index. Ultimately, the researchers found that people with higher TyG levels were up to four times more likely to have rapid cognitive decline compared to those who were lower on the scale. For starters, this type of blood test isn't actually new. We're just discovering new ways it can be used. The TyG index is already used to look for insulin resistance in people, so technically, you could get this test now if your doctor thought that it was medically appropriate. Just know that it's usually used in the context of diabetes or when your doctor suspects you might have diabetes. The test appears to be pretty accurate in predicting rapid mental decline. The researchers found that people with high TyG ended up losing more than 2.5 points on the Mini Mental State Examination per year, which is a standardized test used to look at cognitive function in older adults. In Alzheimer's disease, insulin resistance is thought to interfere with how the brain uses glucose (blood sugar). It's also believed to promote the build-up of amyloid, or proteins deposits in the brain that are linked with Alzheimer's disease. Additionally, insulin resistance can disrupt the blood-brain barrier and fuel inflammation in the brain. All of these are linked with neurodegenerative diseases like Alzheimer's disease. 'Insulin resistance often reflects features of overall health," says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University, pointing out that a major contributor to insulin resistance is higher bodyweight. 'If the overall health of the body is not optimal, then the brain will not be well supported and can be less resilient.' But the link between insulin resistance and Alzheimer's disease is still being explored, says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. So, while it's clear that it seems to play some role, it's hard to tell what it's specifically doing as it relates to brain health. Your doctor can order one of these tests for you. However, neurologists say there are better options right now if you're concerned about Alzheimer's disease development and are looking for answers. 'Some tests that are more specific for Alzheimer's are serum amyloid and tau levels,' Dr. Sachdev sys. 'Tests that help predict risk for the anti-amyloid therapies used in Alzheimer's is the APO-E genotype. These studies are useful today in understand risk of dementia, type of dementia, and risk of treatment.' Dr. Segil says that doctors are 'extremely cautious' about using blood tests like TyG to determine if someone is at risk for developing dementia in the first place. 'There remains an extremely high number of false positive results in patients receiving various blood tests being marketed to determine if you are at risk for getting dementia,' he says. However, this specific study is exploring the test to see how quickly someone who already has cognitive decline will progress—and that usage is still being explored. All of this doesn't mean you can't or shouldn't get a TyG test. Just know that your doctor is more likely to use it while checking you for early signs of diabetes versus Alzheimer's disease right now. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Yahoo
13-06-2025
- Yahoo
A New Study Reveals There's A Specific Diet Linked To A Significantly Lower Dementia Risk
A new study suggests that a specific diet could lower your dementia risk. Researchers analyzing data from nearly 93,000 American adults found that those who closely followed the MIND diet had a 9 percent lower risk of developing dementia. The MIND diet stands for Mediterranean–DASH Intervention for Neurodegenerative Delay. If you've been paying attention to health and wellness headlines over the past few years, you'll already know that your diet impacts everything from gut health to energy levels, but new research suggests it may even influence your dementia risk. That's the major takeaway from the study, which was presented at the American Society for Nutrition's annual meeting. The study pinpoints a specific eating plan—the MIND diet—as having a meaningful impact on dementia risk. Of course, following a specific diet won't automatically wipe away any risk of developing dementia, but neurologists say these new findings are worth paying attention to. Here's why that is, and what they make of the results. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University For the study, researchers analyzed data from nearly 93,000 American adults who participated in the Multiethnic Cohort Study, a long-term study that started in the '90s. At the start of the study, the participants were between 45 and 75 years old. During the study period, more than 21,000 developed Alzheimer's disease or related dementias. The researchers discovered that study participants who closely followed the MIND diet had a 9 percent lower risk of developing dementia. There was a difference in race, too: People who were African American, Latino, or White had a 13 percent lower risk. But the researchers also discovered that people who followed the MIND diet more closely over 10 years, even if they weren't super consistent at the start of the study, had a 25 percent lower risk of dementia compared to those who stopped adhering as much to the eating plan over time. The MIND diet stands for Mediterranean–DASH Intervention for Neurodegenerative Delay. It's an iteration of the Mediterranean diet that is focused on eating plant-based foods with the goal of preventing dementia, according to the National Institute on Aging (NIA). The MIND diet encourages people to focus on eating green leafy vegetables, berries, whole grains, beans, and nuts. It also encourages followers to have olive oil and one or more weekly servings of fish, while limiting red meat, sweets, cheese, butter and margarine, and fast and fried food, per the NIA. The study didn't find that following a MIND diet caused a drop in dementia risk—it just found a link between people who followed the diet and lower risk. But neurologists say there could be something behind this link. 'The MIND diet is generally a balanced diet that manages portion control and offers a diversity of food choices,' says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University. 'This approach offers benefits for improving cardiovascular and cerebrovascular health. By improving blood flow to the brain, overall brain health can be improved.' Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, agrees. 'Eating healthy prevents cardiovascular and cerebrovascular disease which, in turn, prevents heart attacks and strokes,' he says. That question is still under investigation, Dr. Segil says. 'Many diets have been proposed to decrease your risk of getting Alzheimer's dementia as we age and it still remains challenging to see any diet is 'neuro-protective' against getting Alzheimer's dementia,' he adds. Still, Dr. Segil suggests that it may be best to avoid diets that are high in fats and sugars, and limit simple carbohydrates and ultra-processed foods. (All of these food factors have been linked to bodily inflammation, which is associated with dementia risk.) 'Eating a balanced diet of proteins, vegetables, and vitamins, and drinking water are healthy choices which can make you more healthy—and maybe your brain more healthy,' he says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
